According to new findings, "The first-line bortezomib appears to be associated with a heightened risk of falls in the elderly MM patients.
The study, printed in the Journal of Geriatric Oncology, also showed that the patients who have a fall within the 1'st year on bortezomib face a higher risk of mortality. The specialists cautioned that further research is required to confirm the findings.
Respective author Kelly L. Schoenbeck, MD, of the University of California San Francisco, and colleagues, elaborated that the older patients have an increased risk of falls in general, and older adults with cancer have been shown to have an increased risk of falling than matched controls without cancer.
Causes for that risk include functional and cognitive impairment, high-risk medications, depression, frailty, and certain other factors.
The disease multiple myeloma primarily is responsible in order to impact the older adults, with a median age of 70 at the time of diagnosis.
MM is often treated with the PI bortezomib, a medication that has been associated with the peripheral neuropathy.
Schoenbeck and colleagues consequently assumed that the patients taking treatment with the medication might face an increased risk of falls; although, that premise had not yet been assessed in the scientific analysis.
Schoenbeck and colleagues chose to consult the Surveillance, Epidemiology, and End Results (SEER) Program-Medicare database in order to point out patients 65 years old and older, diagnosed with the multiple myeloma b/w 2007 and 2013 and were enrolled in the Medicare parts A, B, or D.
All the patients who met inclusion criteria and started multiple myeloma therapy within the 6-months of diagnosis were included, and their records were analyzed through 2014 to find claims related to the treatment of cancer, falls, and certain covariates.
The specialists recognized 4084 older adults, diagnosed with the multiple myeloma and met inclusion criteria.
Of those, 271 (6 percent) had the fall-related claims in the year before starting the treatment, and a similar number, 259 (6 percent), had falls in the initial 12 months following the treatment (the median time to fall was 129 days).
Only a tiny minority of patients with a fall (8%) had falls in the pre- and post-treatment initiation periods.
Of the over 4000 patients included in the carried out study, half patients (2052) were taken the bortezomib as first-line therapy.
Of those, 157 (8 percent) have a fall within 12 months of the treatment, in comparison to the just 192 (5 percent) patients who did not take the bortezomib injection.
Researchers also showed that diagnostic codes for the peripheral neuropathy were more common in the population of bortezomib (27.7% vs 14.8%), and those with the peripheral neuropathy were more likely to have the falls, findings demonstrated.
According to the translation of multivariate analysis the findings into a 36 percent increased risk for the falls among the patients with bortezomib.
Further assessment exposed that among patients, survived at least 1-year following the starting of treatment, the median overall survival of patients who have a fall was noted as 35.7 months, in comparison to 49.1 percent for those who did not have a fall. Thus, the 1'st year fall was linked with a 26 percent higher risk of death.
Schoenbeck and colleagues wrote, “We assume the mechanism b/w bortezomib and falls among multiple myeloma patients is the treatment-related neuropathy.”
“In support of this, we ended up that the bortezomib, peripheral neuropathy, and falls are all linked,” Schoenbeck and colleagues added.
Though, the authors also cautioned that it was not possible to conclusively draw a causal link up, in part due to the codes for symptoms like peripheral neuropathy may exist themselves considerably earlier than they occur in the claims of Medicare, making it hard to know the appropriate temporal link up between the symptoms as well as the fall.
Researchers stated further study is crucial, in part because if bortezomib (Velcade) increases the risk of falls, those falls occur in order to increase the death risk.
On behalf of conclusion, “Given the protective tendency of the falls, it will be imperative that the future research focus on the prospective fall risk evaluations and interventions that may mitigate fall risks in this patient population.”
Reference:
Related:- Bortezomib medication guide